Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Genetic variants in cytokine genes linked to CAD in new study

Certain variations in genes that encode cytokines — signaling molecules involved in immune responses — may predispose people toward the development of cold agglutinin disease (CAD), a new study suggests. The study, “Cytokine polymorphisms in patients with autoimmune hemolytic anemia,” was published in Frontiers in…

BioCryst eyes oral treatment candidate for CAD by 2025

BioCryst is working to develop a new oral therapy for cold agglutinin disease (CAD) that suppresses the immune complement cascade, and expects to have a lead candidate selected by 2025. This and other drug development plans were shared recently by the biotech company in a “R&D Day”…

Pre-treatments helped limit complications of CAD during surgery

In people with cold agglutinin disease (CAD), pre-treatment with rituximab and plasma exchange may help limit complications during surgeries where the patient’s body temperature is decreased, a new report illustrates. The case study, “Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after…

Man’s CAD likely a complication of ICI cancer therapies

In rare cases, cold agglutinin disease (CAD) may develop as a delayed complication of a combination of immune-activating cancer therapies called immune checkpoint inhibitors (ICIs), according to a case report. While some cases of autoimmune hemolytic anemia (AIHA) — a group of autoimmune disorders that include CAD secondary to…

Scientists report 4th case of daratumumab controlling CAD

Daratumumab, which is approved to treat some cancers, was effective at controlling cold agglutinin disease (CAD) in an elderly woman who failed to respond to rituximab, a study reports. The report, “Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature,”…